Healthcare Global Enterprises Limited (HCG), India's largest provider of cancer care, has announced a significant investment plan to strengthen its wholly owned subsidiaries. The company's Board of Directors, in a meeting held on November 12, 2025, approved investments totaling INR 150 crore in three of its subsidiaries.

Investment Breakdown

The approved investments are as follows:

Purpose and Timeline

The investments are intended for repayment of dues, working capital, and general corporate purposes. HCG plans to complete these cash investments by March 31, 2026, maintaining its 100% ownership in all three subsidiaries.

Subsidiary Profiles

HCG Kolkata Cancer Care LLP

• Operates a 74-bed comprehensive cancer hospital in Kolkata
• Revenue for FY 2024-25: INR 82.14 crore

HCG Oncology Hospitals LLP (formerly known as HCG Borivali)

• Owns a 69-bed comprehensive cancer hospital in Borivali, Mumbai
• Revenue for FY 2024-25: INR 90.38 crore

HCG NCHRI Oncology LLP (HCG Nagpur)

• Operates diagnostic business under the brand name "Triesta"
• Manages PET-CT and Cyclotron business in Chennai
• Revenue for FY 2024-25: INR 89.80 crore

Financial Performance of Subsidiaries

The subsidiaries have shown consistent revenue growth over the past three years:

This investment decision comes as part of HCG's strategy to strengthen its position in key markets and enhance operational capabilities across its network. The move is expected to support the growth and expansion of these subsidiaries, potentially leading to improved cancer care services in their respective regions.

HealthCare Global Enterprises Limited continues to focus on expanding its comprehensive cancer care network across India, reinforcing its commitment to providing advanced cancer care services to a wider population.

Healthcare Global Enterprises Limited (HCG), India's largest provider of cancer care, has announced two significant strategic decisions aimed at strengthening its presence in the African healthcare market. The company's Board of Directors has approved an investment in its Kenyan subsidiary and a financial guarantee to support its expansion plans.

Investment in Cancer Care Kenya Limited

HCG's board has given the green light for acquiring up to 10% of the shares in Cancer Care Kenya Limited (CCK), a step-down subsidiary of the company. The investment, valued at up to INR 7.00 crore, is expected to be completed by March 31, 2026. This move underscores HCG's commitment to expanding its oncology services in the East African region.

CCK operates a comprehensive cancer hospital in Nairobi, offering radiation and chemotherapy services, including a 15-bed Day Care Centre. The subsidiary has shown remarkable growth, with its revenue surging from INR 9.07 crore to INR 42.53 crore. Moreover, CCK reported a profit after tax of INR 10.83 crore, highlighting its strong financial performance.

Financial Guarantee for Business Expansion

In addition to the equity investment, HCG's board has approved the issuance of a Standby Letter of Credit (SBLC) to secure a USD 1.8 million (approximately INR 16.00 crore) term loan for CCK. This financial backing is intended to support CCK's business expansion plans in Kenya.

The company's potential liability under this guarantee is capped at 105% of CCK's outstanding loan amount. HCG will treat this guarantee as a contingent liability on its balance sheet.

Strategic Implications

These decisions reflect HCG's strategic focus on strengthening its international presence, particularly in the African healthcare market. By increasing its stake in CCK and providing financial support for expansion, HCG aims to capitalize on the growing demand for specialized cancer care services in Kenya and potentially the broader East African region.

Dr. B.S. Ajaikumar, Executive Chairman of HCG, stated, "Our investment in Cancer Care Kenya Limited aligns with our vision of bringing advanced cancer care to more patients across borders. We see significant potential in the Kenyan market and are committed to supporting CCK's growth and expansion plans."

The move is expected to not only enhance HCG's global footprint but also contribute to improving cancer care infrastructure in Kenya, potentially setting the stage for further expansion in the African continent.

As HCG continues to execute its growth strategy, investors and industry observers will be keenly watching how these international investments impact the company's overall financial performance and market position in the coming years.